Perpetrator-confessed abusive head trauma cases linked to retinal haemorrhages

Article

The incidence of retinal haemorrhages in abusive head trauma in paediatric patients for known perpetrators, regardless of a confession, is similar, reveals a paper.

The incidence of retinal haemorrhages in abusive head trauma in paediatric patients for known perpetrators, regardless of a confession, is similar, reveals a paper.

A retrospective chart review led by Dr Majida Gaffar, Department of North Shore-Long Island Jewish Health Systems, Great Neck, New York, evaluated the relationship between the presence of retinal haemorrhages and identified perpetrators in 48 cases of abusive head trauma.

All abusive head trauma cases were categorized into perpetrator confessed (Category A), perpetrator identified without confession (Category B) and no perpetrator identified (Category C).

There were 18 cases in category A, 16 in B and 14 in C with retinal haemorrhages in 88%, 75% and 43% of patients in A, B and C, respectively. There was a statistically significant difference in presence of retinal haemorrhages between categories with the perpetrator identified and no perpetrator identified.

Difference in retinal haemorrhages was linked to higher incidence of acute presentation in the perpetrators identified groups compared to category C. Decreased occurrence of retinal haemorrhages was statistically correlated to a lower incidence of acute presentation in abusive head trauma cases without an identified perpetrator.

The abstract can be read in the Journal of Paediatric Ophthalmology and Strabismus.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.